Nuvation Bio Inc

Stock Chart, Company Information, and Scan Results

$4.60(as of Apr 10, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Nuvation Bio Inc Company Information, Fundamentals, and Technical Indicators

Stock Price$4.60
Ticker SymbolNUVB
ExchangeNyse
SectorHealthcare
IndustryBiotechnology
Employees298
CountyUSA
Market Cap$1,598.9M

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+ non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York.

Nuvation Bio Inc In Our Stock Scanner

As of Apr 13, 2026
As of ---
As of ---
As of ---
As of ---
As of ---
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.